Body language: The function of PML nuclear bodies in apoptosis regulation

Cell Death and Differentiation

Volumn 10, Issue 12, 2003, Pages 1290-1299

  Hofmann, Thomas G ^a   Will, H ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Apoptosis; CD95 (Fas APO 1); p53; PML nuclear body; Post translational modification

Indexed keywords

ARSENIC TRIOXIDE; FAS ANTIGEN; HOMEODOMAIN PROTEIN; PROTEIN KINASE; PROTEIN P53; RETINOIC ACID; SUMO 1 PROTEIN;

APOPTOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL NUCLEUS INCLUSION BODY; CELL STRUCTURE; CELLULAR DISTRIBUTION; GENOTOXICITY; HUMAN; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL NUCLEUS; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SUMO-1 PROTEIN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 0346147033     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401313     Document Type: Review

References (148)

1. Spector DL (2001) Nuclear domains. J. Cell Sci. 114: 2891-2893
2. Borden KL (2002) Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell. Biol. 22: 5259-5269
3. Dyck JA, Maul GG, Miller WJ, Chen JD, Kakizuka A and Evans RM (1994) A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76: 333-343
4. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A and Dejean A (1994) Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76: 345-356
5. 3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193: 1361-1372
6. Muratani M, Gerlich D, Janicki SM, Gebhard M, Eils R and Spector DL (2002) Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat. Cell Biol. 4: 106-110
7. Wiesmeijer K, Molenaar C, Bekeer IM, Tanke HJ and Dirks RW (2002) Mobile foci of Sp100 do not contain PML: PML bodies are immobile but PML and Sp100 proteins are not. J. Struct. Biol. 140: 180-188
8. Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ and Chen JD (2000) Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol. Cell. Biol. 20: 1784-1796
9. Zhong S, Salomoni P and Pandolfi PP (2000) The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2: E85-E90
10. Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani F, Pozzan T, Nicoletti I, Grignani F and Pelicci PG (1998) Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 16: 2905-2913
11. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S and Borden KL (2001) PML RING suppresses oncogenic transformation by reducing the affinity of elF4E for mRNA. EMBO J. 20: 4547-4559
12. Everett RD (2001) DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20: 7266-7273
13. Regad T and Chelbi-Alix MK (401) Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20: 7274-7286
14. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP and Pelicci PG (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210
15. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C and Lowe SW (2000) PML is included by oncogenic ras and promotes premature senescence. Genes Dev. 14: 2015-2027
16. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG and Dejean A (2002) Deconstructing PML-induced premature senescence. EMBO J. 21: 3358-3369
17. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG and Kouzarides T (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21: 2383-2396
18. Salomoni P and Pandolfi PP (2002) The role of PML in tumor suppression. Cell 108: 165-170
19. Bischof O; Kim SH, Irving J, Beresten S, Ellis NA and Campisi J (2001) Regulation and localization of the bloom syndrome protein in response to DNA damage. J. Cell Biol. 153: 367-380
20. Carbone R, Pearson M, Minucci S and Pelicci PG (2002) PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 21: 1633-1640
21. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R and Pandolfi PP (1998) PML is essential for multiple apoptotic pathways. Nat. Genet. 20: 266-272
22. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C and Del Sal G (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19: 6185-6195
23. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W and Pandolfi PP (2000) The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2: 730-736
24. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E and Soddu S (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4: 11-19
25. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, Will H and Schmitz ML (2002) Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4: 1-10
26. Zhu J, Lallemand-Breitenbach V and de The H (2001) Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20: 7257-7265
27. de Thé H, Chomienne C, Lanotte M, Degos L and Dejean A (1990) The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347: 558-561
28. Borrow J, Goddard AD, Sheer D and Solomon E (1990) Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249: 1577-1580
29. Goddard AD, Borrow J, Freemont PS and Solomon E (1991) Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254: 1371-1374
30. Kakizuka A, Miller Jr WH, Umesono K, Warrell Jr RP, Frankel SR, Murty VV, Dmitrovsky E and Evans RM (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674
31. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T, Ichikawa-Iwata E, Zhong S, Pandolfi PP and Ishii S (2001) Role of pml and pml-raralpha in mad-mediated transcriptional repression. Mol. Cell 7: 1233-1243
32. Zhu J, Chen Z, Lallemand-Breitenbach V and de The H (2002) How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer 2: 705-713
33. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S and Pelicci PG (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079-1082
34. Le XF, Yang P and Chang KS (1996) Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J. Biol. Chem. 271: 130-135
35. Saurin AJ, Borden KLB, Boddy MN and Freemont PS (1996) Does this have a familiar RING? Trends Biochem. Sci. 21: 208-214
36. Jensen K, Shiels C and Freemont PS (2001) PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223-7233
37. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss Jr JF and Maul GG (1999) PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147: 221-234
38. Zhong S, Müller S, Ronchetti S, Freemont PS, Dejean A and Pandolfi PP (2000) Role of SUMO-1-modified PML in nuclear body formation. Blood 95: 2748-2752
39. Lai HK and Borden KL (2000) The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene 19: 1623-1634
40. Sternsdorf T, Jensen K and Will H (1997) Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell Biol. 139: 1621-1634
41. Jang MS, Ryu SW and Kim E (2002) Modification of Daxx by small ubiquitin-related modifier-1. Biochem. Biophys. Res. Commun. 295: 495-500
42. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M and Del Sal G (1999) Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18: 6462-6471
43. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP and Hay RT (1999) SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18: 6455-6461
44. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson E, Perkins ND and Hay RT (2003) p300 transcriptional repression is mediated by SUMO modification. Mol. Cell 11: 1043-1054
45. Melchior F (2000) SUMO - nonclassical ubiquitin. Annu. Rev. Cell. Dev. Biol. 16: 591-626
46. Desterro JM, Rodriguez MS, Kemp GD and Hay RT (1999) Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 274: 10618-10624
47. Desterro JM, Thomson J and Hay RT (1997) Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett. 417: 297-300
48. Johnson ES and Blobel G (1997) Ubc9p is the conjugating enzyme for the ubiquitin-like protein smt3p. J. Biol. Chem. 272: 26799-26802
49. Kagey MH, Melhuish TA and Wotton D (2003) The Polycomb Protein Pc2 Is a SUMO E3. Cell 113: 127-137
50. Pichler A, Gast A, Seeler JS, Dejean A and Melchior F (2002) The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108: 109-120
51. Kahyo T, Nishida T and Yasuda H (2001) Involvement of PIAS1 in the SUMOlation of tumor suppressor p53. Mol. Cell 8: 713-718
52. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F and Grosschedl R (2001) PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15: 3088-3103
53. Li H and Chen JD (2000) PML and the oncogenic nuclear domains in regulating transcriptional repression. Curr. Opin. Cell Biol. 12: 641-644
54. Best JL, Ganiatsas S, Agarwal S, Changou A, Salomoni P, Shirihai O, Meluh PB, Pandolfi PP and Zon LI (2002) SUMO-1 protease-1 regulates gene transcription through PML. Mol. Cell 10: 843-855
55. Sapetschnig A, Rischitor G, Braun H, Doll A, Schergaut M, Melchior F and Suske G (2002) Transcription factor Sp3 is silenced through SUMO modification by PIAS1. EMBO J. 21: 5206-5215
56. Matunis MJ (2002) On the road to repair: PCNA encounters SUMO and ubiquitin modifications. Mol. Cell 10: 441-442
57. Jackson PK (2001) A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev. 15: 3053-3058
58. Vaux DL, Haecker G and Strasser A (1994) An evolutionary perspective on apoptosis. Cell 76: 777-779
59. Ameisen JC (2002) On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Differ. 9: 367-393
60. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462
61. Krammer PH (2000) CD95's deadly mission in the immune system. Nature 407: 789-795
62. Ross CA (2002) Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35: 819-822
63. Igney FH and Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2: 277-288
64. Strasser A, O'Connor L and Dixit VM (2000) Apoptosis signaling. Annu. Rev. Biochem. 69: 217-245
65. Vercammen D, Brouckaert G, Denecker G, Van de Craen M, Declercq W, Fiers W and Vandenabeele P (1998) Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J. Exp. Med. 188: 919-930
66. Vercammen D, Beyaert R, Denecker G, Goossens V, Van Loo G, Declercq W, Grooten J, Fiers W and Vandenabeele P (1998) Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187: 1477-1485
67. Salvesen GS and Dixit VM (1999) Caspase activation: the induced-proximity model. Proc. Natl. Acad. Sci. USA 96: 10964-10970
68. Puthalakath H and Strasser A (2002) Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9: 505-512
69. Wang X (2001) The expanding role of mitochondria in apoptosis. Genes Dev. 15: 2922-2933
70. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620
71. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14: 5579-5588
72. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH and Peter ME (1997) FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16: 2794-2804
73. Fischer U, Janicke RU and Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell. Death Differ. 10: 76-100
74. Rokudai S, Fujita N, Kitahara O, Nakamura Y and Tsuruo T (2002) Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol. Cell. Biol. 22: 8695-8708
75. Dijkers PF, Medema RH, Lammers JW, Koenderman L and Coffer PJ (2000) Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 10: 1201-1204
76. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ and El-Deiry WS (2002) BID regulation by p53 contributes to chemosensitivity. Nat. Cell Biol. 4: 842-849
77. Nakano K and Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7: 683-694
78. Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7: 673-682
79. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M and Krammer PH (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188: 2033-2045
80. Tanikawa C, Matsuda K, Fukuda S, Nakamura Y and Arakawa H (2003) p53RDL1 regulates p63-dependent apoptosis. Nat. Cell Biol. 5: 216-223
81. Liu ZG, Hsu H, Goeddel DV and Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87: 565-576
82. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM (1996) Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787-789
83. Wang CY, Mayo MW and Baldwin Jr AS (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787
84. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS and Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
85. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C and Gronemeyer H (2001) Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7: 680-606
86. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC and de Thé H (1998) PML induces a novel caspase-independent death process. Nat. Genet. 20: 259-265
87. Morgan M, Thorburn J, Pandolfi PP and Thorburn A (2002) Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms. J. Cell Biol. 157: 975-984
88. Hsu H, Xiong J and Goeddel DV (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81: 495-504
89. Kim YH, Choi CY, Lee SJ, Conti MA and Kim Y (1998) Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J. Biol. Chem. 273: 25875-25879
90. Hofmann TG, Mincheva A, Lichter P, Droge W and Lienhard Schmitz M (2000) Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinases and maps to chromosome 7q32-q34. Biochimie 82: 1123-1127
91. Choi CY, Kim YH, Kwon HJ and Kim Y (1999) The homeodomain protein NK-3 recruits Groucho and a histone deacetylase complex to repress transcription. J. Biol. Chem. 274: 33194-33197
92. Moilanen AM, Karvonen U, Poukka H, Janne OA and Palvimo JJ (1998) Activation of androgen receptor function by a novel nuclear protein kinase. Mol. Biol. Cell. 9: 2527-2543
93. Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, Viglietto G, Santoro M, Chiariotti L and Fusco A (2001) High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 20: 6132-6341
94. Li X, Wang Y, Debatin KM and Hug H (2000) The serine/threonine kinase HIPK2 interacts with TRADD, but not with CD95 or TNF-R1 in 293T cells. Biochem. Biophys. Res. Commun. 277: 513-517
95. Rochat-Steiner V, Becker K, Micheau O, Schneider P, Burns K and Tschopp J (2000) FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. J. Exp. Med. 192: 1165-1174
96. Screaton RA, Kiessling S, Sansom OJ, Millar CB, Maddison K, Bird A, Clarke AR and Frisch SM (2003) Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis. Proc. Natl. Acad. Sci. USA 100: 5211-5216
97. Hua ZC, Sohn SJ, Kang C, Cado D and Winoto A (2003) A function of fas-associated death domain protein in cell cycle progression localized to a single amino acid at its C-terminal region. Immunity 18: 513-521
98. Scaffidi C, Volkland J, Blomberg I, Hoffmann I, Krammer PH and Peter ME (2000) Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J. Immunol. 164: 1236-1242
99. Zhang J, Cado D, Chen A, Kabra NH and Winoto A (1998) Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/MORT1. Nature 392: 296-300
100. Yang X, Khosravi-Far R, Chang HY and Baltimore D (1997) Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89: 1067-1076
101. Chang HY, Nishitoh H, Yang X, Ichijo H and Baltimore D (1998) Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281: 1860-1863
102. Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D and Pandolfi PP (2000) Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J. Exp. Med. 191: 631-640
103. Gongora R, Stephan RP, Zhang Z and Cooper MD (2001) An essential role for Daxx in the inhibition of B lymphopoiesis by type I interferons. Immunity 14: 727-737
104. Raoul C, Estevez AG, Nishimune H, Cleveland DW, deLapeyriere O, Henderson CE, Haase G and Pettmann B (2002) Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 35: 1067-1083
105. Torii S, Egan DA, Evans RA and Reed JC (1999) Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs). EMBO J. 18: 6037-6049
106. Li R, Pei H, Watson DK and Papas TS (2000) EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes, Oncogene 19: 745-753
107. Lehembre F, Muller S, Pandolfi PP and Dejean A (2001) Regulation of Pax3 transcriptional activity by SUMO-1 -modified PML. Oncogene 20: 1-9
108. Emelyanov AV, Kovac CR, Sepulveda MA and Birshtein BK (2002) The interaction of Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells. J. Biol. Chem. 277: 11156-11164
109. Pluta AF, Earnshaw WC and Goldberg IG (1998) Interphase-specific association of intrinsic centromere protein CENP-C with hDaxx, a death domain-binding protein implicated in Fas-mediated cell death. J. Cell Sci. 111: 2029-2041
110. Ko YG, Kang YS, Park H, Seol W, Kim J, Kim T, Park HS, Choi EJ and Kim S (2001) Apoptosis signal-regulating kinase 1 controls the proapoptotic function of death-associated protein (Daxx) in the cytoplasm. J. Biol. Chem. 276: 39103-39106
111. Charette SJ, Lambert H and Landry J (2001) A kinase-independent function of Ask1 in caspase-independent cell death. J. Biol. Chem. 276: 36071-36074
112. Charette SJ and Landry J (2000) The interaction of HSP27 with Daxx identifies a potential regulatory role of HSP27 in Fas-induced apoptosis. Ann. NY Acad. Sci. 926: 126-131
113. Perlman R, Schiemann WP, Brooks MW, Lodish HF and Weinberg RA (2001) TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell Biol. 3: 708-714
114. Ecsedy JA, Michaelson JS and Leder P (2003) Homeodomain-interacting protein kinase 1 modulates daxx localization, phosphorylation, and transcriptional activity. Mol. Cell. Biol. 23: 950-960
115. Michaelson JS, Bader D, Kuo F, Kozak C and Leder P (1999) Loss of daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development. Genes Dev. 13: 1918-1923
116. Michaelson JS and Leder P (2003) RNAi reveals anti-apoptotic and transcriptionally repressive activities of DAXX. J. Cell Sci. 116: 345-352
117. Ohiro Y, Usheva A, Kobayashi S, Duffy SL, Nantz R, Gius D and Horikoshi N (2003) Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53. Mol. Cell. Biol. 23: 322-334
118. Xu D, Wilson TJ, Chan D, De Luca E, Zhou J, Hartzog PJ and Kola I (2002) Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells. EMBO J. 21: 4081-4093
119. Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
120. Kubbutat MH, Jones SN and Vousden KH (1997) Regulation of p53 stability by Mdm2, Nature 387: 299-303
121. Haupt Y, Maya R, Kazaz A and Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299
122. Lundberg AS, Hahn WC, Gupta P and Weinberg RA (2000) Genes involved in senescence and immortalization. Curr. Opin. Cell Biol. 12: 705-709
123. Oren M (1999) Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274: 36031-36034
124. Caelles C, Helmberg A and Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223
125. Haupt Y, Rowan S, Shaulian E, Vousden KH and Oren M (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9: 2170-2183
126. Marchenko ND, Zaika A and Moll UM (2000) Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275: 16202-16212
127. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P and Moll UM (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 11: 577-590
128. Wahl GM and Carr AM (2001) The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat. Cell Biol. 3: E277-E286
129. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E and Kastan MB (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11: 3471-3481
130. Shieh SY, Ikeda M, Taya Y and Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334
131. Raveh T, Droguett G, Horwitz MS, DePinho RA and Kimchi A (2001) DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat. Cell Biol. 3: 1-7
132. Sherr CJ (2001) The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2: 731-737
133. Campisi J (2001) Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 11: S27-S31
134. Lain S, Midgley C, Sparks A, Lane EB and Lane DP (1999) An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp. Cell Res. 248: 457-472
135. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP and Haupt Y (2003) PML protects p53 from Mdm2-mediated inhibition and degradation. J. Biol. Chem. 16: 16
136. Yang S, Kuo C, Bisi JE and Kim MK (2002) PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat. Cell Biol. 4: 865-870
137. Everett RD, Meredith M, Orr A, Cross A, Kathoria M and Parkinson J (1997) A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16: 566-577
138. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J and Gu W (2002) Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648-653
139. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y and Taya Y (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862
140. Gu W, Shi XL and Roeder RG (1997) Synergistic activation of transcription by CBP and p53. Nature 387: 819-823
141. Lill NL, Grossman SR, Ginsberg D, DeCaprio J and Livingston DM (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-827
142. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175-1184
143. Kwek SS, Derry J, Tyner AL, Shen Z and Gudkov AV (2001) Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 20: 2587-2599
144. Schmidt D and Muller S (2002) Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. USA 99: 2872-2877
145. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L and Weinberg RA (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159
146. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L and Gu W (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148
147. Engelhardt OG, Boutell C, Orr A, Ullrich E, Haller O and Everett RD (2003) The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML. Exp. Cell Res. 283: 36-50
148. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP and Chang KS (2003) Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J. Biol. Chem. 278: 12294-12304